346 related articles for article (PubMed ID: 26702474)
21. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.
Tobisawa S; Honma M; Ishida-Yamamoto A; Saijo Y; Iizuka H
J Dermatol Sci; 2013 Sep; 71(3):160-6. PubMed ID: 23702390
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Duarte RF; Canals C; Onida F; Gabriel IH; Arranz R; Arcese W; Ferrant A; Kobbe G; Narni F; Deliliers GL; Olavarría E; Schmitz N; Sureda A
J Clin Oncol; 2010 Oct; 28(29):4492-9. PubMed ID: 20697072
[TBL] [Abstract][Full Text] [Related]
24. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract][Full Text] [Related]
25. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases.
Fauconneau A; Pham-Ledard A; Cappellen D; Frison E; Prochazkova-Carlotti M; Parrens M; Dalle S; Joly P; Viraben R; Franck F; Ingen-Housz-Oro S; Giacchero D; Jullié ML; Vergier B; Merlio JP; Beylot-Barry M
Br J Dermatol; 2015 Jun; 172(6):1547-1554. PubMed ID: 25645336
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
27. Recognizing large-cell transformation of mycosis fungoides.
Herrmann JL; Hughey LC
J Am Acad Dermatol; 2012 Oct; 67(4):665-72. PubMed ID: 22261416
[TBL] [Abstract][Full Text] [Related]
28. Mycosis fungoides/Sézary syndrome: report of an unusual case.
Mehta A; Dhungel BM; Khan MF
J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Factors and Survival Outcomes Among Patients With Mycosis Fungoides in China: A 12-Year Review.
Chen Z; Lin Y; Qin Y; Qu H; Zhang Q; Li Y; Wen Y; Sun J; Tu P; Gao P; Wang Y
JAMA Dermatol; 2023 Oct; 159(10):1059-1067. PubMed ID: 37585188
[TBL] [Abstract][Full Text] [Related]
30. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study.
O'Donnell M; Zaya R; Correia E; Krishnasamy S; Sahu J; Shi W; Cha J; Alpdogan SO; Porcu P; Nikbakht N
J Am Acad Dermatol; 2022 Jun; 86(6):1285-1292. PubMed ID: 34273458
[TBL] [Abstract][Full Text] [Related]
31. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
[TBL] [Abstract][Full Text] [Related]
32. Mycosis fungoides with large cell transformation (CD30+) and B-cell chronic lymphocytic leukemia.
Petković M; Ilić I; Jurakić Tončić R; Radman-Livaja I; Čeović R
Acta Dermatovenerol Croat; 2023 Dec; 31(4):223-224. PubMed ID: 38651850
[TBL] [Abstract][Full Text] [Related]
33. Spatially Resolved Transcriptomes of CD30+-Transformed Mycosis Fungoides and Cutaneous Anaplastic Large-Cell Lymphoma.
Choi ME; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
J Invest Dermatol; 2024 Feb; 144(2):331-340.e2. PubMed ID: 37544586
[TBL] [Abstract][Full Text] [Related]
34. Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides.
van Santen S; Roach RE; van Doorn R; Horváth B; Bruijn MS; Sanders CJ; de Pooter JC; van Rossum MM; de Haas ER; Veraart JC; Bekkenk MW; Vermeer MH; Willemze R
JAMA Dermatol; 2016 Sep; 152(9):992-1000. PubMed ID: 27276223
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
Diamandidou E; Colome M; Fayad L; Duvic M; Kurzrock R
J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):914-24. PubMed ID: 10365922
[TBL] [Abstract][Full Text] [Related]
36. Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium.
Kadin ME; Hughey LC; Wood GS
J Am Acad Dermatol; 2014 Feb; 70(2):374-6. PubMed ID: 24438952
[No Abstract] [Full Text] [Related]
37. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
38. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
39. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
40. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides.
Li JY; Pulitzer MP; Myskowski PL; Dusza SW; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2013 Sep; 69(3):366-74. PubMed ID: 23685027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
